Multiple gastrointestinal stromal tumors in neurofibromatosis type 1;Multiple gastrointestinale stromatumoren bei neurofibromatose typ 1

Medizinische Klinik

Volumn 102, Issue 2, 2007, Pages 163-167

  Zachäus, Markus ^a,b   Plötner, Andreas ^a   Weimann, Arved ^a   Ruf, Bernhard ^a  

^a Klinikum St Georg   (Germany)

^b Park Krankenhaus Leipzig Sudost GmbH   (Germany)

Author keywords

c kit; CD117; GIST; Neurofibromatosis; Stromal tumor

Indexed keywords

ADULT; ARTICLE; CASE REPORT; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HISTORY; HUMAN; MALE; METASTASIS; NEUROFIBROMATOSIS; RECURRENT DISEASE; SMALL INTESTINE RESECTION; SMALL INTESTINE TUMOR;

BIOPSY; ENDOSCOPY; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; JEJUNAL NEOPLASMS; JEJUNUM; MALE; MELENA; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; NEUROFIBROMATOSIS 1; PROTO-ONCOGENE PROTEINS C-KIT; RISK FACTORS; TIME FACTORS;

EID: 33847417510     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1018-3     Document Type: Article

References (36)

1. Zoller ME, Rembeck B, Oden A, et al. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125-31.
2. Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 1991;19:1-11.
3. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors. The incidence, prevalence, clinical course and prognostication in the pre-imatinib-era: a population-based study in Western Sweden. Cancer 2005;103:821-29.
4. Köppen S, Wejda B, Dormann A, et al. Gastrointestinale Stromatumoren des Jejunums bei einer Patientin mit Neurofibromatose Typ 1. Z Gastroenterol 2004;42:1183-7.
5. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunhistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
6. Kramer K, Siech M, Sträter J, et al. Hämorrhagischer Schock bei Doppel-Malignom: gastrointestinaler Stromatumor (GIST) und neuroendokrines Karzinom bei Morbus Recklinghausen. Z Gastroenterol 2005;43:281-8.
7. Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005;29:755-63.
8. Andersson J, Sihto H, Meis-Kindblom JM, et al. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 2005;29:1170-6.
9. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-25.
10. Shinomura Y, Kinoshita K, Tsutsui S, et al. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol 2005;40:775-80.
11. Yantiss RK, Rosenberg AE, Sarran L, et al. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol 2005;18:475-84.
12. Lee JL, Kim JY, Ryu MH, et al. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal tumors associated with neurofibromatosis type 1. Dig Dis Sci 2006;51:1043-6.
13. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
14. Schlemmer M, Milani V, Tschoep K, et al. Gastrointestinale Stromatumoren. Dtsch Med Wochenschr 2003;128:2015-9.
15. Fletcher CD, Jules JB, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2003;33:459-65.
16. Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients. J Pathol 2004;202:80-5.
17. Maertens O, Prenen H, Debiec-Rychter M, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Gen 2006;15:1015-23.
18. Miettinen M, Fetsch JF, Sobin LH, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis 1. A clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol 2006;30:90-6.
19. Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behaviour and management. Ann Surg Oncol 2000;7:705-12.
20. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
21. Loughrey MB, Mitchell C, Mann GB, et al. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 2005;58:779-81.
22. Bümming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003;89:460-4.
23. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24 2325-31.
24. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-75.
25. Connolly EM, Gaffney M, Reynolds JV. Gastrointestinal stromal tumours. Br J Surg 2003;90:1178-86.
26. Benjamin RS, Blanke CD, Blay JY, et al. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. Oncologist 2006;11:9-20.
27. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-93.
28. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7.
29. Salazar M, Barata A, Andre S, et al. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Gut 2006;55:585-6.
30. Shah JN, Sun W, Seethala RR, et al. Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc 2005;61:625-7.
31. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006;368:1303-4.
32. Marx J. Encouraging results for second-generation antiangiogenesis drugs. Science 2005;308:1248-9.
33. Morabito A, De Maio E, Di Maio M, et al. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64.
34. Weisberg E, Wright RD, Jiang J, et al. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006;131:1734-42.
35. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-9.
36. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2005;38:Suppl:S60-5.